NSTL国家科技图书文献中心

1. Occlusive Vasculitis Following Intravitreal Rituximab Injection for Primary Vitreoretinal Lymphoma NSTL国家科技图书文献中心

Cole, Emily D. | Dedania, Vaidehi ... - 《Ocular immunology and inflammation》 - 2025,33(1) - 161～165 - 共5页

摘要： were following an injection of Rituxan (rituximab | vasculitis following intravitreal rituximab* therapy for* | biosimilar Riabni (rituximab-arrx, AmGen) and two of which | following intravitreal injection of rituximab. The initial | complication of intravitreal rituximab* therapy in patients*

关键词： Biosimilar | intravitreal rituximab | occlusive vasculitis | primary vitreoretinal lymphoma | panuveitis

2. Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab NSTL国家科技图书文献中心

Kogias, Dionysios | Gavriilidis, Efstrat...... - 《Journal of viral hepatitis.》 - 2025,32(3) - e70005～e70005 - 共8页

摘要： thrombotic thrombocytopenic purpura treated with rituximab | Hepatitis E virus (HEV) infection is a | frequent cause of acute viral hepatitis | . Immunocompromised patients, especially those under anti-CD20 | regimens, are prone to chronic or treatment-resistant

关键词： hepatitis E | immunosuppression | ribavirin | rituximab

3. Development of a time-resolved fluoroimmunoassay for rituximab and its application to therapeutic drug monitoring NSTL国家科技图书文献中心

Kao, Shangbin | Liu, Xiaobin ... - 《Clinica chimica acta》 - 2025,568 - Article 120142～Article 120142 - 共8页

摘要：Background: Rituximab* pharmacokinetics in* | measurement of serum rituximab* concentrations is essential* | fluoroimmunoassay (TRFIA) for rituximab* (rituximab-TRFIA) with a* | -type rituximab-TRFIA was developed using streptavidin | -coated microplates, biotinylated anti-rituximab

关键词： Therapeutic drug monitoring | Membranous nephropathy | Pharmacokinetics | Rituximab | Time-resolved fluoroimmunoassay

4. Rituximab Induced Flare of Psoriatic Arthritis in a Patient with Devic's Syndrome: A Case Report NSTL国家科技图书文献中心

Gonzales, Sofia Audr... | Mortezaei, Kiana ... - 《Current rheumatology reviews》 - 2025,21(1) - 109～112 - 共4页

摘要：, numbness, and vision problems. Rituximab* has mainly been* | that rituximab* is efficient and well tolerated in* | possibility of rituximab* exacerbating severe psoriasis and* | involvement who responded exceptionally well to rituximab | . After withdrawing from the use of rituximab, her

关键词： Rituximab | psoriatic arthritis | devic's syndrome | inflammation | autoimmune disorder | numbness

5. Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma NSTL国家科技图书文献中心

Camilla Mazzoni | Lisa Argnani ... - 《European Journal of Haematology》 - 2025,114(1) - 70～78 - 共9页

摘要： disease. Single‐agent rituximab* is a useful approach in* | effectiveness and safety of single‐agent rituximab* (375 mg/m2* | analyzed. Median time between diagnosis and rituximab* was* | easily manageable. Single‐agent rituximab* may represent* | ABSTRACT First‐line therapy for patients with

关键词： extranodal marginal zone lymphoma | frontline treatment | rituximab

6. Nocardiosis in systemic lupus erythematosus patients treated with rituximab: Report of two cases and systematic review of literature NSTL国家科技图书文献中心

Gil-Rodriguez, Jaime | Fernandez, Javier de...... - 《Lupus》 - 2025,34(3) - 316～325 - 共10页

摘要： rituximab and nocardiosis remains unclear.Cases ReportA 55 | , immunoglobulins, rituximab, and azathioprine. She developed | rituximab. He developed infections in the lungs, prostate | (rituximab) AND (nocardia), with a timeframe up to 15 March | Nocardia infection in SLE patients treated with rituximab

关键词： Systemic lupus erythematosus | rituximab | nocardia

7. Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review NSTL国家科技图书文献中心

Koji,Suzuki | Mitsuhiro,Akiyama ... - 《Rheumatology international.》 - 2025,45(1) - Article: 12～Article: 12 - 共10页

摘要： cardiovascular events. Given that rituximab* has been reported* | with rituximab. Furthermore, our review of the | rituximab. These findings suggest that rituximab serves as | Abstract Immunoglobulin G4-related disease | (IgG4-RD) is an immune-mediated disorder characterized

关键词： Immunoglobulin G4-related disease | Rituximab | Anti-CD20 monoclonal antibody | Coronary artery stenoses

8. Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review NSTL国家科技图书文献中心

Guan, Rong-Yan | Tang, Xing-Ru ... - 《Recent patents on anti-cancer drug discovery》 - 2025,20(1) - 121～130 - 共10页

摘要： lymphocytes. Rituximab* is a chimeric monoclonal antibody to* | rituximab monotherapy with other available treatment | SMZL with villous lymphocytes treated by rituximab | applied rituximab* monotherapy. After eight cycles of* | rituximab treatment, the patient's condition improved

关键词： Splenic marginal zone lymphoma | rituximab | monotherapy | case report | immunotargeted therapy | meta analysis

9. Economic Evaluation of Rituximab Versus Corticosteroid-Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea NSTL国家科技图书文献中心

Heejung Choi | Yoon Cho ... - 《Nephrology.》 - 2025,30(6) - e70063～e70063 - 共11页

摘要： drug reactions (ADRs). Rituximab* has a non-inferior* | . However, the high cost of rituximab* is a* | costs of rituximab* versus corticosteroid* | parameters and estimate the appropriate price of rituximab | . Results: The total expected cost for rituximab* was $4132*

关键词： ; rituximab; steroid.

10. Efficacy and safety of rituximab in patients with lupus nephritis: systematic review and meta-analysis A NSTL国家科技图书文献中心

Tang, Zhiming | Huang, Yanqin ... - 《Clinical nephrology》 - 2025,103(1) - 53～62 - 共10页

摘要： evaluate the efficacy and safety of rituximab* (RTX) in* | Background: Our aim was to systematically | patients with lupus nephritis (LN). Materials and methods | : PubMed, Embase, China National Knowledge Infrastructure | (CNKI), Cochrane Library, and Wanfang Databases were

关键词： Biosimilar | intravitreal rituximab | occlusive vasculitis | primary vitreoretinal lymphoma | panuveitis

摘要： thrombotic thrombocytopenic purpura treated with rituximab | Hepatitis E virus (HEV) infection is a | frequent cause of acute viral hepatitis | . Immunocompromised patients, especially those under anti-CD20 | regimens, are prone to chronic or treatment-resistant

关键词： hepatitis E | immunosuppression | ribavirin | rituximab

摘要：Background: Rituximab* pharmacokinetics in* | measurement of serum rituximab* concentrations is essential* | fluoroimmunoassay (TRFIA) for rituximab* (rituximab-TRFIA) with a* | -type rituximab-TRFIA was developed using streptavidin | -coated microplates, biotinylated anti-rituximab

关键词： Therapeutic drug monitoring | Membranous nephropathy | Pharmacokinetics | Rituximab | Time-resolved fluoroimmunoassay

摘要：, numbness, and vision problems. Rituximab* has mainly been* | that rituximab* is efficient and well tolerated in* | possibility of rituximab* exacerbating severe psoriasis and* | involvement who responded exceptionally well to rituximab | . After withdrawing from the use of rituximab, her

关键词： Rituximab | psoriatic arthritis | devic's syndrome | inflammation | autoimmune disorder | numbness

关键词： extranodal marginal zone lymphoma | frontline treatment | rituximab

关键词： Systemic lupus erythematosus | rituximab | nocardia

摘要： cardiovascular events. Given that rituximab* has been reported* | with rituximab. Furthermore, our review of the | rituximab. These findings suggest that rituximab serves as | Abstract Immunoglobulin G4-related disease | (IgG4-RD) is an immune-mediated disorder characterized

关键词： Immunoglobulin G4-related disease | Rituximab | Anti-CD20 monoclonal antibody | Coronary artery stenoses

摘要： lymphocytes. Rituximab* is a chimeric monoclonal antibody to* | rituximab monotherapy with other available treatment | SMZL with villous lymphocytes treated by rituximab | applied rituximab* monotherapy. After eight cycles of* | rituximab treatment, the patient's condition improved

关键词： Splenic marginal zone lymphoma | rituximab | monotherapy | case report | immunotargeted therapy | meta analysis

摘要： drug reactions (ADRs). Rituximab* has a non-inferior* | . However, the high cost of rituximab* is a* | costs of rituximab* versus corticosteroid* | parameters and estimate the appropriate price of rituximab | . Results: The total expected cost for rituximab* was $4132*

关键词： ; rituximab; steroid.

摘要： evaluate the efficacy and safety of rituximab* (RTX) in* | Background: Our aim was to systematically | patients with lupus nephritis (LN). Materials and methods | : PubMed, Embase, China National Knowledge Infrastructure | (CNKI), Cochrane Library, and Wanfang Databases were

关键词： rituximab | anti-CD20 monoclonal antibody | lupus nephritis | meta analysis

4008-161-200 800-990-8900

国家科技图书文献中心

关键词： Biosimilar | intravitreal rituximab | occlusive vasculitis | primary vitreoretinal lymphoma | panuveitis

摘要： thrombotic thrombocytopenic purpura treated with rituximab | Hepatitis E virus (HEV) infection is a | frequent cause of acute viral hepatitis | . Immunocompromised patients, especially those under anti-CD20 | regimens, are prone to chronic or treatment-resistant

关键词： hepatitis E | immunosuppression | ribavirin | rituximab

摘要：Background: Rituximab pharmacokinetics in | measurement of serum rituximab concentrations is essential | fluoroimmunoassay (TRFIA) for rituximab (rituximab-TRFIA) with a | -type rituximab-TRFIA was developed using streptavidin | -coated microplates, biotinylated anti-rituximab

关键词： Therapeutic drug monitoring | Membranous nephropathy | Pharmacokinetics | Rituximab | Time-resolved fluoroimmunoassay

摘要：, numbness, and vision problems. Rituximab has mainly been | that rituximab is efficient and well tolerated in | possibility of rituximab exacerbating severe psoriasis and | involvement who responded exceptionally well to rituximab | . After withdrawing from the use of rituximab, her

关键词： Rituximab | psoriatic arthritis | devic's syndrome | inflammation | autoimmune disorder | numbness

关键词： extranodal marginal zone lymphoma | frontline treatment | rituximab

关键词： Systemic lupus erythematosus | rituximab | nocardia

摘要： cardiovascular events. Given that rituximab has been reported | with rituximab. Furthermore, our review of the | rituximab. These findings suggest that rituximab serves as | Abstract Immunoglobulin G4-related disease | (IgG4-RD) is an immune-mediated disorder characterized

关键词： Immunoglobulin G4-related disease | Rituximab | Anti-CD20 monoclonal antibody | Coronary artery stenoses

摘要： lymphocytes. Rituximab is a chimeric monoclonal antibody to | rituximab monotherapy with other available treatment | SMZL with villous lymphocytes treated by rituximab | applied rituximab monotherapy. After eight cycles of | rituximab treatment, the patient's condition improved

关键词： Splenic marginal zone lymphoma | rituximab | monotherapy | case report | immunotargeted therapy | meta analysis

摘要： drug reactions (ADRs). Rituximab has a non-inferior | . However, the high cost of rituximab is a | costs of rituximab versus corticosteroid | parameters and estimate the appropriate price of rituximab | . Results: The total expected cost for rituximab was $4132

关键词： ; rituximab; steroid.

摘要： evaluate the efficacy and safety of rituximab (RTX) in | Background: Our aim was to systematically | patients with lupus nephritis (LN). Materials and methods | : PubMed, Embase, China National Knowledge Infrastructure | (CNKI), Cochrane Library, and Wanfang Databases were

关键词： rituximab | anti-CD20 monoclonal antibody | lupus nephritis | meta analysis

4008-161-200 800-990-8900

国家科技图书文献中心

摘要：Background: Rituximab* pharmacokinetics in* | measurement of serum rituximab* concentrations is essential* | fluoroimmunoassay (TRFIA) for rituximab* (rituximab-TRFIA) with a* | -type rituximab-TRFIA was developed using streptavidin | -coated microplates, biotinylated anti-rituximab

摘要：, numbness, and vision problems. Rituximab* has mainly been* | that rituximab* is efficient and well tolerated in* | possibility of rituximab* exacerbating severe psoriasis and* | involvement who responded exceptionally well to rituximab | . After withdrawing from the use of rituximab, her

摘要： cardiovascular events. Given that rituximab* has been reported* | with rituximab. Furthermore, our review of the | rituximab. These findings suggest that rituximab serves as | Abstract Immunoglobulin G4-related disease | (IgG4-RD) is an immune-mediated disorder characterized

摘要： lymphocytes. Rituximab* is a chimeric monoclonal antibody to* | rituximab monotherapy with other available treatment | SMZL with villous lymphocytes treated by rituximab | applied rituximab* monotherapy. After eight cycles of* | rituximab treatment, the patient's condition improved

摘要： drug reactions (ADRs). Rituximab* has a non-inferior* | . However, the high cost of rituximab* is a* | costs of rituximab* versus corticosteroid* | parameters and estimate the appropriate price of rituximab | . Results: The total expected cost for rituximab* was $4132*

摘要： evaluate the efficacy and safety of rituximab* (RTX) in* | Background: Our aim was to systematically | patients with lupus nephritis (LN). Materials and methods | : PubMed, Embase, China National Knowledge Infrastructure | (CNKI), Cochrane Library, and Wanfang Databases were